---
type: research
topic: "BioFit: Generative Design for Biomanufacturing - Comprehensive Business Plan"
date: 2026-01-13
assessment: ANSWERED
confidence: HIGH
rounds: 2
vault_sources: 0
web_sources: 35+
---

# BioFit: Generative Design for Biomanufacturing Facilities

## A Comprehensive Business Plan for Arco Murray Partnership

---

# Executive Summary

**The Opportunity:** The biomanufacturing facility construction market is experiencing unprecedented growth—$155B+ in CDMO spending with 7-10% CAGR through 2033. Facilities cost $350-$1,000+/sq ft and take 18-36 months to design and build. Yet no software exists to automate facility layout optimization for GMP-compliant manufacturing.

**The Inspiration:** TestFit proved generative design works for "commodity" buildings (multifamily, industrial), generating 3,000 layouts in 3 seconds. They've raised $22M at ~$10k/year per customer. The insight: biomanufacturing constraints are equally parametric—GMP classifications, cleanroom specs, process flows, equipment footprints.

**The Product:** BioFit—a generative design platform that inputs site constraints, GMP requirements, and process parameters, then outputs hundreds of compliant facility layouts ranked by cost, time-to-start, and operational flexibility.

**The Partnership:** Arco Murray is the ideal partner. They have FlexShell (proprietary modular biomanufacturing design), 60+ life sciences projects (5M+ sq ft), and relationships with J&J, GSK, Bayer, and MilliporeSigma. Their design-build model means faster exploration = more competitive wins.

**The Ask:** Co-develop BioFit with Arco Murray. They contribute domain expertise and customer relationships. The startup builds the constraint engine. Target: $50-100k/project pricing on $50M+ facilities.

---

# Section 1: Market Opportunity

## 1.1 The Biomanufacturing Buildout Wave

The pharmaceutical and biomanufacturing sectors are in the midst of a multi-decade capacity expansion:

| Market Segment | 2024 Size | 2033 Projection | CAGR |
|----------------|-----------|-----------------|------|
| Pharmaceutical CDMO | $155.5B | $293.6B | 7.4% |
| Biopharmaceutical Contract Manufacturing | $39.2B | $95.1B | 10.4% |
| U.S. CMO/CDMO | $83.1B (2025) | — | 8.7% |
| Biologics CDMO | +$16.3B growth | — | 13.7% |
| Cell & Gene Therapy Manufacturing | $32.1B (2025) | $403.5B (2035) | 28.8% |

*Sources: [Grand View Research](https://www.grandviewresearch.com/industry-analysis/pharmaceutical-cdmo-market-report), [Straits Research](https://straitsresearch.com/report/biopharmaceutical-contract-manufacturing-market), [Future Market Insights](https://www.futuremarketinsights.com/reports/cell-and-gene-therapy-manufacturing-market)*

## 1.2 Major Facility Investments (2024-2025)

The industry is committing billions to new capacity:

| Company | Investment | Location | Capacity |
|---------|------------|----------|----------|
| Fujifilm Diosynth | $3.2B | Holly Springs, NC | 8 × 20,000L bioreactors |
| Samsung Biologics | Campus II | Songdo, Korea | 1,324,000L by 2032 |
| Lotte Biologics | $3.3B | Songdo, Korea | Bio Campus |
| Thermo Fisher | $2B | USA (St. Louis) | 4 × 5,000L bioreactors |
| Lonza | $1.2B acquisition | Genentech site | 332,000L, 19 bioreactors |
| Novo Holdings | $16.5B | Catalent acquisition | Fill-finish capacity |

*Source: [Grand View Research Biomanufacturing Trends](https://www.grandviewresearch.com/market-trends/biomanufacturing-capacity-expansion-regional-footprint-landscape-trend-analysis)*

## 1.3 Why This Creates Software Demand

**Every facility project involves design iteration pain:**

- **Cost:** $6M for small GMP facilities, $100M+ for commercial-scale
- **Timeline:** 18-36 months from concept to operational
- **Complexity:** GMP compliance, cleanroom classifications, process flows, equipment coordination
- **Risk:** Overbuilding strains finances; underbuilding kills growth

The design phase—layout optimization, equipment placement, compliance verification—is still largely manual. Engineers iterate through CAD, review with stakeholders, estimate costs, repeat. Each cycle takes days to weeks.

**The calculation:**
- A tool that saves 3 months on a $50M project is worth $500k+ to the client
- A tool that finds the layout hitting $450/sq ft instead of $800/sq ft saves $millions
- A tool that de-risks the build-vs-buy decision prevents existential mistakes

---

# Section 2: The TestFit Model

## 2.1 What TestFit Proved

TestFit (Dallas, $22M raised) demonstrated that generative design works for buildings when you properly encode constraints:

**The Technical Approach:**
- **Not AI/ML:** Deterministic constraint-based algorithms, not neural networks
- **Constraint Engine:** 160+ variables including zoning, building codes, unit mixes, parking ratios
- **Performance:** 3,000 layouts in 3 seconds on a standard laptop; 25,000 in 10 seconds
- **Architecture:** 20-30 algorithms running in parallel to "satisfy all constraints and present a solution as close as possible to what the user requested"

**The Business Model:**

| Tier | Price | Key Feature |
|------|-------|-------------|
| Urban Planner | $100/mo | Massing studies |
| Data Maps | $400/mo | Site analysis, zoning data |
| Site Solver | $10k/year | Generative design |
| Enterprise | Custom | Volume discounts |

**The Results:**
- 4-10x faster site planning
- 92% of customers close deals faster
- 650+ deals evaluated weekly
- ENR Top 500 adoption

*Sources: [TestFit Generative Design](https://www.testfit.io/product/generative-design), [Engineering.com Analysis](https://www.engineering.com/a-first-look-at-testfit-generative-design/)*

## 2.2 Why Biomanufacturing is the Right Vertical

TestFit's founder Clifton Harness identified the key insight: "Without a proper constraint engine that encompasses almost everything, the goals to achieve are useless."

**Biomanufacturing constraints are highly parametric:**

| Constraint Category | Examples |
|---------------------|----------|
| Regulatory/Classification | ISO 14644 (ISO 5-8), GMP grades (A-D), Annex 1, BSL levels |
| Process Flow | Personnel/material separation, gowning cascades, airlocks |
| Equipment | Bioreactor footprints, chromatography skids, CIP systems |
| HVAC/Utilities | Air change rates by class, utility corridors, waste pathways |
| Financial | Cost/sq ft by zone, expansion modularity, multi-product flexibility |

**These rules exist**—they're codified in ISPE Baseline Guides, FDA regulations, and equipment vendor specs. They just haven't been encoded into generative software.

*Source: [ISPE Biopharmaceutical Manufacturing Facilities Guide](https://ispe.org/publications/guidance-documents/biopharmaceuticals)*

---

# Section 3: Competitive Landscape Analysis

## 3.1 Current Market: Fragmented Tools, No Integrated Solution

| Tool/Vendor | What It Does | Gap |
|-------------|--------------|-----|
| **Dassault 3DEXPERIENCE** | Digital twins for process optimization | NOT facility layout generation |
| **Autodesk Generative** | Mechanical part optimization | NOT regulated building design |
| **PlantStream** | Piping and process design | NOT facility-level planning |
| **Wiskind CleanCube** | Cleanroom panel layout optimization | Only walls/panels, not full facility |
| **SimScale CFD** | Airflow simulation | Post-design validation, not generation |
| **BIM Tools (Revit, etc.)** | Model what you've designed | Don't generate designs |
| **KeyPlants** | Modular facility components | Manual integration, not generative |

**The Gap:** No one has built the "TestFit constraint engine" for GMP-compliant biomanufacturing facilities.

## 3.2 Why Hasn't This Been Built?

1. **Domain expertise barrier:** Encoding ISPE guidelines + Annex 1 + vendor equipment specs requires deep GMP knowledge
2. **Small apparent market:** Looks niche to horizontal software players
3. **High-stakes validation:** Wrong constraints = non-compliant designs = liability
4. **Customer concentration:** A few hundred design-build firms globally

**The opportunity:** These barriers are features, not bugs. They create defensible moat for whoever builds it first.

## 3.3 Competitive Analysis: AEC Firms in Life Sciences

| Firm | Life Sciences Focus | Proprietary Tools | Vulnerability |
|------|---------------------|-------------------|---------------|
| **CRB** | #2 in pharma design | None public | Manual process |
| **Jacobs** | $50B+ in projects | Internal digital tools | Slow iteration |
| **Genesis AEC** | Pure-play life sciences | None public | Manual process |
| **Arcadis** | Growing focus | Digital twin for process | Not layout |
| **ARCO/Murray** | 60 projects, 5M+ SF | **FlexShell modular design** | Opportunity partner |

*Sources: [CRB Pharmaceuticals](https://www.crbgroup.com/pharmaceuticals), [Jacobs Life Sciences](https://www.jacobs.com/what-we-do/life-sciences), [ARCO Life Science Projects](https://www.arconational.com/life-science-and-pharmaceutical-projects/)*

---

# Section 4: Product Architecture

## 4.1 Core System Design

### Input Layer

**Site Parameters:**
- Footprint geometry (CAD import or draw)
- Ceiling height constraints
- Existing infrastructure (brownfield)
- Expansion zones

**GMP Requirements:**
- Target ISO classification by zone
- GMP grade requirements (A/B/C/D)
- Annex 1 compliance requirements
- BSL levels (if applicable)

**Process Specification:**
- Process type: mAb, cell therapy, viral vector, fill/finish
- Capacity targets (L/year, batch size)
- Multi-product flexibility requirements
- Campaign duration assumptions

**Equipment Library:**
- Bioreactor vendors/models (Cytiva, Sartorius, Pall)
- Chromatography system footprints
- Fill/finish equipment dimensions
- Utility equipment (HVAC, CIP, WFI)

### Constraint Engine

**Regulatory Constraints:**
- Personnel/material flow separation (unidirectional)
- Gowning room cascade requirements
- Airlock staging sequences
- Air change rates by classification
- Pressure differential requirements

**Spatial Constraints:**
- Equipment clearance zones
- Maintenance access requirements
- Utility corridor routing rules
- Emergency egress paths

**Operational Constraints:**
- Material transfer patterns
- Sampling point accessibility
- Cleaning validation requirements
- Environmental monitoring placement

### Output Layer

**Generated Layouts:**
- Floor plans with zone classifications
- Equipment placement overlays
- Personnel flow diagrams
- Material flow diagrams
- Utility routing schematics

**Ranking Metrics:**
- Cost/sq ft by zone type
- Time-to-operational estimate
- Operational flexibility score
- Expansion capacity rating
- GMP compliance confidence

**Export Formats:**
- Revit/AutoCAD native
- BIM-compatible
- PDF reports with annotations
- Cost modeling spreadsheets

## 4.2 Technical Architecture

Following TestFit's proven approach:

```
┌─────────────────────────────────────────────────────┐
│                    User Interface                    │
│         (Web-based, architect-friendly terms)        │
└─────────────────────┬───────────────────────────────┘
                      │
┌─────────────────────▼───────────────────────────────┐
│              Parameter Definition Layer              │
│  (Site geometry, GMP requirements, process type)     │
└─────────────────────┬───────────────────────────────┘
                      │
┌─────────────────────▼───────────────────────────────┐
│              CONSTRAINT ENGINE (CORE IP)             │
│  ┌─────────────┐  ┌─────────────┐  ┌─────────────┐  │
│  │ Regulatory  │  │  Spatial    │  │ Operational │  │
│  │ Constraints │  │ Constraints │  │ Constraints │  │
│  └─────────────┘  └─────────────┘  └─────────────┘  │
│                                                      │
│  ┌─────────────────────────────────────────────────┐│
│  │     Deterministic Layout Generation Algorithms   ││
│  │     (NOT ML - rule-based, like TestFit)          ││
│  └─────────────────────────────────────────────────┘│
└─────────────────────┬───────────────────────────────┘
                      │
┌─────────────────────▼───────────────────────────────┐
│              Layout Ranking Engine                   │
│      (Cost, timeline, flexibility, compliance)       │
└─────────────────────┬───────────────────────────────┘
                      │
┌─────────────────────▼───────────────────────────────┐
│              Export & Integration Layer              │
│           (Revit, AutoCAD, BIM, PDF)                 │
└─────────────────────────────────────────────────────┘
```

## 4.3 MVP Scope (Phase 1)

**Target Use Case:** mAb production facility, 10,000-50,000 sq ft, single-product

**Constraint Library v1:**
- ISO 7/8 cleanroom zones
- Standard mAb process flow (upstream → downstream → fill)
- 3 bioreactor vendor templates (Cytiva, Sartorius, Pall)
- Personnel/material unidirectional flow
- Basic utility corridor routing

**Output v1:**
- 2D floor plans with zone coloring
- Personnel flow diagram
- Cost estimate by zone
- Export to AutoCAD DWG

**Success Metric:** Generate 100+ compliant layouts in <60 seconds, matching or exceeding what a junior engineer produces in 2 weeks

---

# Section 5: Go-to-Market Strategy

## 5.1 Why Arco Murray

**Strategic Fit:**

| Arco Murray Asset | BioFit Leverage |
|-------------------|-----------------|
| **FlexShell modular design** | Already partially parameterized—lowest-effort first product |
| **60+ life sciences projects** | Training data for constraint validation |
| **5M+ sq ft delivered** | Credibility with enterprise clients |
| **Design-build model** | Faster decision loops = more tool value |
| **J&J, GSK, Bayer relationships** | Distribution channel to top 20 pharma |
| **30% schedule savings claim** | BioFit amplifies their existing value prop |

**Arco Murray Project Examples:**

| Project | Size | Client Type |
|---------|------|-------------|
| Confidential | 700,000 SF | Drug Manufacturing Campus |
| Lonza | 315,000 SF | Pharmaceutical Manufacturing |
| Aurobindo Pharma | 567,000 SF | Pharmaceutical Manufacturing |
| Phase 3 Real Estate | 213,500 SF | Office & Laboratory |
| Camber Development | 174,000 SF | Advanced Manufacturing |

*Source: [ARCO Life Science Projects](https://www.arconational.com/life-science-and-pharmaceutical-projects/)*

## 5.2 Partnership Models

**Option A: Co-Development Partnership**
- Arco Murray contributes: Domain expertise, project data, pilot customers, equity investment
- Startup contributes: Engineering team, product development, IP
- Revenue: Joint sales, revenue share on Arco-sourced deals
- Exit: Arco Murray has right of first refusal to acquire

**Option B: Exclusive Licensing**
- Startup builds product independently
- Arco Murray gets exclusive license for design-build use (non-compete with other D-B firms)
- Annual licensing fee: $500k-$2M
- Usage fees: $25-50k per project

**Option C: Acquisition**
- Arco Murray acquires early-stage company
- Founders stay to build product within Arco
- Arco owns category-defining tool

**Recommended: Option A** — Arco Murray gets strategic value; startup gets domain expertise and distribution; both aligned on success.

## 5.3 Pricing Strategy

**Value-Based Pricing Framework:**

| Project Size | Traditional Design Cost | BioFit Value | BioFit Price |
|--------------|-------------------------|--------------|--------------|
| Small (<25k SF) | $500k-$1M | Save 2-4 weeks | $25k |
| Medium (25-100k SF) | $1-3M | Save 1-2 months | $50k |
| Large (>100k SF) | $3-10M+ | Save 3-6 months | $100-250k |

**Comparison to TestFit:**
- TestFit: $10k/year for unlimited projects
- BioFit: $25-250k/project on $50-500M facilities
- **10-25x higher ACV** justified by higher-stakes decisions

**Alternative: Enterprise SaaS**
- Annual license: $200k-$500k
- Unlimited projects
- Target: Top 20 design-build firms + CDMOs with internal design teams

## 5.4 Expansion Roadmap

**Year 1:** mAb production facilities (Arco Murray pilot)
**Year 2:** Add cell therapy, viral vector, fill/finish templates
**Year 3:** Expand to other design-build firms (CRB, Jacobs, Genesis)
**Year 4:** Direct to CDMOs (Lonza, Samsung, Fujifilm) for internal planning
**Year 5:** International expansion (EU Annex 1, PMDA Japan requirements)

---

# Section 6: Financial Model

## 6.1 Market Sizing

**TAM (Total Addressable Market):**
- ~500 biomanufacturing facility projects globally per year
- Average project size: $50M
- Design/engineering: ~5-8% of project cost = $2.5-4M
- **TAM = $1.25-2B in annual design spend**

**SAM (Serviceable Addressable Market):**
- U.S. + EU markets: ~60% of global projects = 300 projects
- Facilities >$10M where tool provides value: ~200 projects
- **SAM = $500M-$800M annually**

**SOM (Serviceable Obtainable Market, Year 5):**
- 50 projects/year × $75k average price = **$3.75M ARR**
- With enterprise licenses: **$5-10M ARR**

## 6.2 Unit Economics

| Metric | Value | Notes |
|--------|-------|-------|
| Average Contract Value | $75k | Blended across project sizes |
| Gross Margin | 85%+ | Software, minimal COGS |
| CAC | $25k | Enterprise sales cycle |
| LTV | $300k+ | Multi-project relationships |
| LTV/CAC | 12x | Highly efficient |
| Payback Period | 6 months | Single deal covers CAC |

## 6.3 Development Investment

**Phase 1 (MVP): $1.5-2M**
- 4 engineers × 12 months
- GMP domain consultant
- Pilot customer development with Arco Murray

**Phase 2 (Product-Market Fit): $3-5M**
- Expand constraint library
- Enterprise sales team (2-3 AEs)
- Customer success for implementation

**Phase 3 (Scale): $10-15M**
- International expansion
- Equipment vendor integrations
- CDMO direct sales channel

**Total to Profitability: $15-20M over 4-5 years**

## 6.4 Comparable Valuations

| Company | Stage | Valuation | Revenue Multiple |
|---------|-------|-----------|------------------|
| TestFit | Series A | ~$100M (implied) | ~20x ARR |
| Procore | Public | $9B | ~12x revenue |
| Autodesk | Public | $50B | ~10x revenue |

**BioFit at $10M ARR = $100-200M valuation** (vertical SaaS premium)

---

# Section 7: Risk Analysis

## 7.1 Technical Risks

| Risk | Likelihood | Impact | Mitigation |
|------|------------|--------|------------|
| Constraint library incomplete | Medium | High | Partner with ISPE, start narrow (mAb only) |
| Performance issues at scale | Low | Medium | Follow TestFit architecture (proven) |
| BIM integration complexity | Medium | Medium | Hire AEC software veterans |

## 7.2 Market Risks

| Risk | Likelihood | Impact | Mitigation |
|------|------------|--------|------------|
| Biomanufacturing buildout slows | Medium | High | Diversify to food/beverage, semiconductor |
| Large pharma builds internally | Low | Medium | CDMOs are growing faster (outsourcing trend) |
| Incumbent response (Autodesk) | Low | Medium | Regulatory complexity is barrier |

## 7.3 Execution Risks

| Risk | Likelihood | Impact | Mitigation |
|------|------------|--------|------------|
| Arco Murray partnership fails | Medium | High | Develop multiple D-B relationships |
| Key engineer departure | Medium | Medium | Equity incentives, redundancy |
| Wrong initial use case | Medium | High | Heavy customer discovery before build |

## 7.4 Regulatory/Liability Risks

| Risk | Likelihood | Impact | Mitigation |
|------|------------|--------|------------|
| Tool generates non-compliant design | Medium | Very High | Heavy validation, disclaimers, PE sign-off required |
| FDA guidance changes | Low | Medium | Modular constraint library, fast updates |

---

# Section 8: The Pitch Deck (5 Slides)

## Slide 1: The Problem

**Biomanufacturing facilities cost $6M-$100M+ and take 18-36 months.**

- Design iteration is manual: layout → review → estimate → repeat
- Every decision ripples through multi-year, high-stakes projects
- Overbuilding strains finances; underbuilding kills growth
- No software automates GMP-compliant facility layout

## Slide 2: The Inspiration

**TestFit proved generative design works for buildings.**

- 3,000 apartment layouts in 3 seconds
- $22M raised, $10k/year customers
- Key insight: Constraints are parametric and encodable

**Biomanufacturing constraints are equally parametric:**
- GMP classifications, cleanroom specs, process flows
- ISPE guidelines, Annex 1, equipment vendor specs
- These rules exist—they just haven't been encoded

## Slide 3: The Product

**BioFit: Generative design for biomanufacturing facilities**

**Inputs:** Site constraints + GMP requirements + process type + equipment library

**Outputs:** Hundreds of compliant layouts in seconds, ranked by cost, timeline, flexibility

**Value:**
- Explore 300 layouts in an afternoon instead of 3 in 6 months
- Find the $450/sq ft design instead of the $800/sq ft default
- De-risk capacity decisions before committing $50M+

## Slide 4: Why Arco Murray

**You're the perfect partner:**

1. **FlexShell is halfway there** — Modular design = constraint library waiting to be parameterized
2. **60+ life sciences projects** — Training data and validation
3. **J&J, GSK, Bayer relationships** — Distribution to top 20 pharma
4. **Design-build model** — Faster exploration = more competitive wins

**The math:**
- Save 3 months on a $50M project = worth $500k+
- Tool costs $50-100k = 5-10x ROI per project

## Slide 5: The Ask

**Partner to build BioFit.**

- **You contribute:** Domain expertise, pilot projects, customer relationships
- **We contribute:** Engineering team, product development
- **Shared outcome:** Category-defining tool, competitive moat

**Alternative:** Acquire early and own the category before CRB or Jacobs figures this out.

---

# Appendix A: Sources

## Market Data
- [Grand View Research - Pharmaceutical CDMO Market](https://www.grandviewresearch.com/industry-analysis/pharmaceutical-cdmo-market-report)
- [Straits Research - Biopharmaceutical Contract Manufacturing](https://straitsresearch.com/report/biopharmaceutical-contract-manufacturing-market)
- [Future Market Insights - CGT Manufacturing](https://www.futuremarketinsights.com/reports/cell-and-gene-therapy-manufacturing-market)
- [Grand View Research - Biomanufacturing Trends](https://www.grandviewresearch.com/market-trends/biomanufacturing-capacity-expansion-regional-footprint-landscape-trend-analysis)

## TestFit Research
- [TestFit Generative Design](https://www.testfit.io/product/generative-design)
- [TestFit Pricing](https://www.testfit.io/pricing)
- [Engineering.com First Look](https://www.engineering.com/a-first-look-at-testfit-generative-design/)
- [Architosh Launch Coverage](https://architosh.com/2024/07/testfit-generative-design-goes-live/)

## Regulatory Standards
- [ISPE Biopharmaceutical Manufacturing Facilities Guide](https://ispe.org/publications/guidance-documents/biopharmaceuticals)
- [ISPE Baseline Guides Overview](https://ispe.org/product-types/baseline-guides)
- [ISPE Challenges in Biopharmaceutical Facility Design](https://ispe.org/pharmaceutical-engineering/ispeak/challenges-and-trends-biopharmaceutical-facility-design)

## Arco Murray / ARCO
- [ARCO Life Science Projects](https://www.arconational.com/life-science-and-pharmaceutical-projects/)
- [ARCO Murray Advanced Manufacturing](https://www.arcomurray.com/advanced-manufacturing-2/)
- [ARCO Life Science Division Announcement](https://www.arconational.com/top-design-build-general-contractor-establishes-life-science-advanced-manufacturing-specialty-division/)

## Facility Costs
- [BioProcess International - Construction Costs](https://www.bioprocessintl.com/facility-design-engineering/construction-and-start-up-costs-for-biomanufacturing-plants)
- [Bandak PM - Biomanufacturing Complexity](https://www.bandakpm.com/blog/navigating-complexity)
- [Cleanroom Technology - Cost Per Square Foot](https://cleanroomtechnology.com/costing-a-cleanroom-per-square-foot-139470)

## Competitive Landscape
- [Dassault Systèmes Biomanufacturing](https://www.3ds.com/industries/life-sciences-healthcare/biomanufacturing)
- [Wiskind CleanCube](https://www.wiskindcleanroom.com/pharmaceutical-cleanroom-layout-concept-to-reality-within-minutes---wiskind-cleancube.html)
- [Jacobs Life Sciences](https://www.jacobs.com/what-we-do/life-sciences)

---

# Appendix B: Constraint Library Specification (v1)

## Regulatory Constraints

### ISO Classification Requirements
| Zone Type | ISO Class | Air Changes/Hr | Particle Limits |
|-----------|-----------|----------------|-----------------|
| Aseptic Core | ISO 5 | 240-600 | 3,520 @ 0.5μm |
| Surrounding | ISO 7 | 60-90 | 352,000 @ 0.5μm |
| Prep/Staging | ISO 8 | 20-40 | 3,520,000 @ 0.5μm |

### GMP Grade Mapping
| Grade | Application | Airflow | Pressure |
|-------|-------------|---------|----------|
| A | Aseptic filling | Unidirectional | +15 Pa |
| B | Background to A | Turbulent | +10 Pa |
| C | Less critical | Turbulent | +5 Pa |
| D | Low-risk | Turbulent | Neutral |

## Process Flow Constraints

### mAb Production (Default Template)
```
Media Prep → Seed Train → Production → Harvest → Purification → Fill/Finish
    ↓           ↓            ↓           ↓           ↓            ↓
  ISO 8       ISO 7        ISO 7       ISO 7       ISO 7        ISO 5
```

### Personnel Flow Rules
- Gowning cascade: Street → Change → Airlock → Grade D → Grade C → Grade B → Grade A
- No backflow without re-gowning
- Minimum 2 airlocks between Grade A and unclassified

### Material Flow Rules
- Dedicated entry for raw materials
- Pass-through for consumables
- Dedicated waste streams per classification
- No material crossing personnel paths

## Equipment Footprints (Initial Library)

| Equipment | Vendor | Footprint | Utilities |
|-----------|--------|-----------|-----------|
| 2000L SUB | Cytiva | 3m × 4m | WFI, CDA, Exhaust |
| 500L SUB | Sartorius | 2m × 3m | WFI, CDA, Exhaust |
| ÄKTA Pilot | Cytiva | 1m × 2m | Buffer, WFI |
| Filling Line | IMA | 6m × 15m | CIP, SIP, N2 |

---

*Report generated: 2026-01-13*
*Classification: Business Confidential*
